Liquiritigenin alleviates inflammation and mitochondrial dysfunction in acute pancreatitis via ERβ–VDAC1 signaling
This study provides the first evidence that liquiritigenin, a selective ERβ agonist, protects against AP by inhibiting VDAC1 oligomerization and preserving mitochondrial homeostasis, thereby reducing inflammatory injury and pancreatic tissue damage. These findings highlight ERβ-VDAC1 signaling as a potential therapeutic target for AP.
Authors
- Yong Chen (ORCID: https://orcid.org/0000-0003-4269-8518)
- Yifan Miao
- Ji‐Hun Mo (ORCID: https://orcid.org/0000-0003-1331-364X)
- Yun Lü (ORCID: https://orcid.org/0000-0003-0664-2664)
- Shao‐Hua Fan (ORCID: https://orcid.org/0000-0003-1878-5902)
- Ding Bai (ORCID: https://orcid.org/0000-0002-5058-4329)
- Hongying Li (ORCID: https://orcid.org/0009-0001-1062-8438)
- Wei Jin (ORCID: https://orcid.org/0000-0002-2905-2109)
- Jiaqi Yao (ORCID: https://orcid.org/0000-0002-7822-910X)
Institutions
- First People's Hospital of Chongqing (CN)
- Chengdu University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Journal of Ethnopharmacology
- Published
- 2025-09-03
- DOI
- https://doi.org/10.1016/j.jep.2025.120526
- Citations
- 3
- Primary Topic
- Pancreatitis Pathology and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 6.02